Updated on 2025/10/15

写真a

 
MATSUYAMA Takahiro
 
Organization
Research Field in Medicine and Health Sciences, Medical and Dental Sciences Area Graduate School of Medical and Dental Sciences Advanced Therapeutics Course Cardiovascular and Respiratory Disorders Assistant Professor
Title
Assistant Professor
Degree
(2021.9 Kagoshima University)

Studying abroad experiences

  • 2023.9 - 2025.8   McMaster University  

 

Papers

  • Matsuyama T, Matsuyama H, Dotake Y, Oniwa M, Tsuruzono K, Uchida H, Yasuda S, Kondo K, Takagi K, Suetsugu T, Iwakawa J, Machida K, Mizuno K, Tanaka K, Inoue H .  Long-term efficacy of mepolizumab on eosinophilic granulomatosis with polyangiitis: a retrospective study .  Exploration of Asthma & Allergy2   461 - 472   2024.9Reviewed International journal

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

  • Matsuyama T., Salter B.M., Emami Fard N., Machida K., Sehmi R. .  TNF Superfamily and ILC2 Activation in Asthma .  Biomolecules14 ( 3 )   2024.3Reviewed International journal

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)   Publisher：Biomolecules  

    Eosinophilic asthma is the most prevalent and well-defined phenotype of asthma. Despite a majority of patients responding to corticosteroid therapy and T2 biologics, there remains a subset that have recurrent asthma exacerbations, highlighting a need for additional therapies to fully ameliorate airway eosinophilia. Group 2 innate lymphoid cells (ILC2) are considered key players in the pathogenesis of eosinophilic asthma through the production of copious amounts of type 2 cytokines, namely IL-5 and IL-13. ILC2 numbers are increased in the airways of asthmatics and with the greatest numbers of activated ILC2 detected in sputa from severe prednisone-dependent asthma with uncontrolled eosinophilia. Although epithelial-derived cytokines are important mediators of ILC2 activation, emerging evidence suggests that additional pathways stimulate ILC2 function. The tumor necrosis factor super family (TNFSF) and its receptors (TNFRSF) promote ILC2 activity. In this review, we discuss evidence supporting a relationship between ILC2 and TNFSF/TNFRSF axis in eosinophilic asthma and the role of this relationship in severe asthma with airway autoimmune responses.

    DOI： 10.3390/biom14030294

    Scopus

    PubMed

  • Hamu-Tanoue A., Takagi K., Taketomi Y., Miki Y., Nishito Y., Kano K., Aoki J., Matsuyama T., Kondo K., Dotake Y., Matsuyama H., Machida K., Murakami M., Inoue H. .  Group III secreted phospholipase A2-driven lysophospholipid pathway protects against allergic asthma .  FASEB Journal38 ( 2 ) e23428   2024.1Reviewed International journal

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：FASEB Journal  

    Asthma is a chronic inflammatory disease of the airways characterized by recurrent episodes of airway obstruction, hyperresponsiveness, remodeling, and eosinophilia. Phospholipase A<inf>2</inf>s (PLA<inf>2</inf>s), which release fatty acids and lysophospholipids from membrane phospholipids, have been implicated in exacerbating asthma by generating pro-asthmatic lipid mediators, but an understanding of the association between individual PLA<inf>2</inf> subtypes and asthma is still incomplete. Here, we show that group III-secreted PLA<inf>2</inf> (sPLA<inf>2</inf>-III) plays an ameliorating, rather than aggravating, role in asthma pathology. In both mouse and human lungs, sPLA<inf>2</inf>-III was expressed in bronchial epithelial cells and decreased during the asthmatic response. In an ovalbumin (OVA)-induced asthma model, Pla2g3<sup>−/−</sup> mice exhibited enhanced airway hyperresponsiveness, eosinophilia, OVA-specific IgE production, and type 2 cytokine expression as compared to Pla2g3<sup>+/+</sup> mice. Lipidomics analysis showed that the pulmonary levels of several lysophospholipids, including lysophosphatidylcholine, lysophosphatidylethanolamine, and lysophosphatidic acid (LPA), were decreased in OVA-challenged Pla2g3<sup>−/−</sup> mice relative to Pla2g3<sup>+/+</sup> mice. LPA receptor 2 (LPA<inf>2</inf>) agonists suppressed thymic stromal lymphopoietin (TSLP) expression in bronchial epithelial cells and reversed airway hyperresponsiveness and eosinophilia in Pla2g3<sup>−/−</sup> mice, suggesting that sPLA<inf>2</inf>-III negatively regulates allergen-induced asthma at least by producing LPA. Thus, the activation of the sPLA<inf>2</inf>-III-LPA pathway may be a new therapeutic target for allergic asthma.

    DOI： 10.1096/fj.202301976R

    Scopus

    PubMed

  • Matsuyama Takahiro, Tanaka Jun, Tone Kazuya, Shimizu Kaoruko, Nakano Takako, Takahashi Koichiro .  THE EFFICACY OF BRONCHIAL THERMOPLASTY IN LONG-TERM MAINTENANCE OF ADULT PATIENTS WITH MODERATE TO SEVERE ASTHMA .  Japanese Journal of Allergology73 ( 1 ) 40 - 51   2024Reviewed

    　More details

    Authorship：Lead author   Language：Japanese   Publishing type：Research paper (scientific journal)   Publisher：Japanese Society of Allergology  

    <p><b>Background and Aims</b>: Bronchial thermoplasty (BT) is a bronchoscopic treatment for adult patients with moderate to severe asthma. A systematic review was conducted to examine the efficacy of this treatment.</p><p><b>Methods</b>: Randomized controlled comparing BT to a control in adult patients with moderate to severe asthma were added to the previously conducted systematic review. Literature published prior to July 2022 was selected.</p><p><b>Results</b>: Four trials were included in this study. BT resulted in significant improvement in quality of life. However, no significant difference in asthma control was observed. Moreover, the incidence of severe adverse events during the treatment period was increased by BT. Furthermore, BT did not improve lung function, increase withdrawal from oral corticosteroids, reduce frequency of rescue medication usage, or increase the number of symptom-free days.</p><p><b>Conclusion</b>: From a risk-benefit perspective, there is insufficient evidence to support a recommendation of BT in adult patients with moderate to severe asthma.</p>

    DOI： 10.15036/arerugi.73.40

    Scopus

    PubMed

    CiNii Research

  • Matsuyama T., Tomioka Y., Matsuyama H., Kamenohara Y., Tanigawa K., Dotake Y., Hagihara Y., Takagi K., Machida K., Inoue H. .  Severe asthma remaining well-controlled after mepolizumab discontinuation: A case report and literature review .  Respirology Case Reports11 ( 6 ) e01158   2023.6Reviewed International journal

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)   Publisher：Respirology Case Reports  

    Mepolizumab, a humanized anti-IL-5 monoclonal antibody used for severe asthma, results in a reduced rate of asthma exacerbation, improved lung function, reduced oral corticosteroid use, and improved quality of life. A 62-year-old man using high-dose inhaled corticosteroid visited our hospital because of poorly-controlled asthma. He had eosinophilia in peripheral blood and sputum, and high levels of fraction of exhaled nitric oxide. Therefore, he was treated with mepolizumab for severe asthma. Mepolizumab treatment resulted in significantly improved pulmonary function and reduced frequencies of asthma exacerbations. Because of his good asthma control, mepolizumab treatment was discontinued after 3 years. Since discontinuing mepolizumab, his asthma control has remained without exacerbation. Previous studies suggest that mepolizumab should be continued to sustain clinical benefits. However, cases of long-term controlled asthma have not been reported after mepolizumab withdrawal, and our case may be instructive.

    DOI： 10.1002/rcr2.1158

    Scopus

    PubMed

  • Matsuyama T., Machida K., Mizuno K., Matsuyama H., Dotake Y., Shinmura M., Takagi K., Inoue H. .  The Functional Role of Group 2 Innate Lymphoid Cells in Asthma .  Biomolecules13 ( 6 )   2023.6Reviewed International journal

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)   Publisher：Biomolecules  

    Asthma is a heterogeneous disease characterized by chronic airway inflammation. Group 2 innate lymphoid cells (ILC2) play an important role in the pathogenesis of asthma. ILC2s lack antigen-specific receptors and respond to epithelial-derived cytokines, leading to the induction of airway eosinophilic inflammation in an antigen-independent manner. Additionally, ILC2s might be involved in the mechanism of steroid resistance. Numerous studies in both mice and humans have shown that ILC2s induce airway inflammation through inflammatory signals, including cytokines and other mediators derived from immune or non-immune cells. ILC2s and T helper type 2 (Th2) cells collaborate through direct and indirect interactions to organize type 2 immune responses. Interestingly, the frequencies or numbers of ILC2 are increased in the blood and bronchoalveolar lavage fluid of asthma patients, and the numbers of ILC2s in the blood and sputum of severe asthmatics are significantly larger than those of mild asthmatics. These findings may contribute to the regulation of the immune response in asthma. This review article highlights our current understanding of the functional role of ILC2s in asthma.

    DOI： 10.3390/biom13060893

    Scopus

    PubMed

  • Matsuyama T., Machida K., Hamu A., Takagi K., Momi H., Higashimoto I., Inoue H. .  Effects of instructional materials on the proper techniques of inhaler device use .  Respiratory Investigation60 ( 5 ) 633 - 639   2022.9Reviewed International journal

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)   Publisher：Respiratory Investigation  

    Background: Inhaled medication is the cornerstone of pharmacological treatment for asthma. Poor inhaler techniques are associated with poor asthma control and an increased risk of exacerbations. Leaflets and videos are provided by several pharmaceutical companies to explain the proper techniques to patients. We investigated the effects of instructional materials (leaflet and video) on the patient's inhaler techniques. Methods: The subjects were 67 medical students at Kagoshima University. They all were provided with two types of inhalation devices: a dry powder inhaler (DPI) and a pressurized metered-dose inhaler (pMDI). The students were assigned to three groups: (1) leaflet, (2) video, and (3) combination (leaflet + video). Pulmonologists observed and assessed the students’ use of the devices by using a validated checklist. The percentage of subjects who avoided critical errors was also assessed. Critical errors were errors that affected drug delivery to the lungs substantially. Results: The percentage of overall competence and the number of steps that were mastered out of the 11 steps were higher in the combination group than those in the other two groups. However, only 40% in the combination group were able to successfully execute every critical step. The percentage of subjects who avoided critical errors was also higher in the combination group than in the other groups. Conclusions: A single form of instructional materials (leaflet or video) was insufficient for acquiring proper inhaler techniques. The combination of two learning materials may help patients with asthma acquire proper inhaler techniques and subsequently, improve their asthma control.

    DOI： 10.1016/j.resinv.2022.04.010

    Scopus

    PubMed

  • Matsuyama T., Matsuyama H., Dotake Y., Takagi K., Machida K., Inoue H. .  The Therapeutic Potential for Targeting Group 2 Innate Lymphoid Cells in Asthma .  Frontiers in Immunology13   930862   2022.7Reviewed International journal

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)   Publisher：Frontiers in Immunology  

    T helper type 2 cells (Th2 cells) and group 2 innate lymphoid cells (ILC2s) play an important role in the pathophysiology of asthma, including airway eosinophilic inflammation. ILC2s are activated by epithelial-derived cytokines [interleukin-25 (IL-25), IL-33, and thymic stromal lymphopoietin (TSLP)] from airway epithelial cells, leading to the release of high amounts of type 2 cytokines, such as IL-5 and IL-13. ILC2s induce airway inflammation in an antigen-independent manner, and ILC2s are considered to be involved in the pathogenesis of asthma exacerbation. Furthermore, ILC2 activation might also confer steroid resistance. Many recent studies in humans and mice are increasingly demonstrating that the function of ILC2s is regulated not just by epithelial-derived cytokines but by a variety of cytokines and mediators derived from innate immune cells. Furthermore, the biologics targeting these cytokines and/or their receptors have been shown to reduce asthma exacerbations and improve lung function and quality of life in asthmatics. This article reviews the current treatment landscape for type 2 airway inflammation in asthma and discusses the therapeutic potential for targeting ILC2s.

    DOI： 10.3389/fimmu.2022.930862

    Scopus

    PubMed

  • Matsuyama T., Machida K., Motomura Y., Takagi K., Doutake Y., Tanoue-Hamu A., Kondo K., Mizuno K., Moro K., Inoue H. .  Long-acting muscarinic antagonist regulates group 2 innate lymphoid cell-dependent airway eosinophilic inflammation .  Allergy76 ( 9 ) 2785 - 2796   2021.9Reviewed International journal

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)   Publisher：Allergy European Journal of Allergy and Clinical Immunology  

    Background: Tiotropium bromide, a long-acting muscarinic antagonist, reduces the frequency of exacerbation in patients with moderate to severe asthma, but its underlying mechanism is not clear. Asthma exacerbations are associated with exposure to external stimuli, and group 2 innate lymphoid cells (ILC2s) are considered to be involved in the pathophysiology of asthma exacerbation. We investigated whether tiotropium modulates airway inflammation through ILC2 functions. Methods: Mice were administered papain intranasally to induce innate-type airway inflammation with or without tiotropium pretreatment, and bronchoalveolar lavage fluids (BALF) and lung tissues were collected. Lung-derived ILC2s and bone marrow-derived basophils were stimulated in vitro with IL-33 in the presence or absence of tiotropium. Muscarinic M3 receptor (M3R) expression on immune cells was assessed by RNA sequence. Results: Papain induced airway eosinophilic inflammation, and tiotropium reduced the numbers of eosinophils in BALF. The concentrations of IL-4, IL-5, and IL-13, and the numbers of ILC2s in BALF were also reduced by tiotropium treatment. However, tiotropium did not affect IL-33-induced IL-5 and IL-13 production from ILC2s, suggesting that tiotropium regulates ILC2s indirectly. Gene-expression analysis showed that basophils predominantly expressed M3R mRNA among murine immune cells. Tiotropium reduced IL-4 production from basophils derived from mouse bone marrow and human basophils after stimulation with IL-33. Conclusions: These findings suggest that tiotropium attenuates ILC2-dependent airway inflammation by suppressing IL-4 production from basophils and, subsequently, regulating ILC2 activation. The inhibitory effects of long-acting muscarinic antagonists on the innate response may contribute to reducing asthma exacerbation.

    DOI： 10.1111/all.14836

    Scopus

    PubMed

  • Matsuyama T., Tanaka K., Kitazono I., Kondo K., Satomura M., Matsuyama H., Sasaki H., Tanimoto A., Taniguchi N., Inoue H. .  Pulmonary metastasis of chondrosarcoma diagnosed by transbronchial lung biopsy after differentiation from organizing pneumonia: A case report .  Respiratory Investigation63 ( 5 ) 998 - 1001   2025.9Reviewed International journal

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)   Publisher：Respiratory Investigation  

    A 49-year-old woman presented with abdominal distention and right leg numbness. Bone biopsy from a huge tumor in her pelvis revealed chondrosarcoma, and proton beam therapy was performed. Although there were no abnormalities at 6 months, dry cough, dyspnea and fever with elevated inflammation appeared at 9 months. Computed tomography showed multiple consolidations in both lungs, different from typical images of nodular shadows with calcification in pulmonary metastases of chondrosarcoma. We first suspected infection or organizing pneumonia, but biopsy revealed chondrosarcoma metastases with severely infiltrated inflammatory cells. Imaging patterns we experienced may reflect inflammatory pathogenesis due to rapid cancer progression.

    DOI： 10.1016/j.resinv.2025.07.017

    Scopus

    PubMed

  • Matsuyama T., Oniwa M., Tsuruzono K., Yasuda S., Yone M., Tomioka Y., Uchida A., Mitsuyama H., Kubota S., Suetsugu T., Mizuno K., Inoue H. .  Improving visual acuity with nivolumab plus ipilimumab plus two cycles of chemotherapy following a diagnosis of lung adenocarcinoma with choroidal metastasis: A case report and literature review .  Respirology Case Reports12 ( 1 ) e01262   2024.1Reviewed International journal

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)   Publisher：Respirology Case Reports  

    A 75-year-old woman presented at our hospital with bilateral visual impairment. Ophthalmological examination revealed multiple choroidal tumours. Chest computed tomography revealed a tumour shadow in the right lower lobe and multiple lymph node metastases in the mediastinum and pulmonary hilum. Following a detailed examination, the patient was diagnosed with primary lung adenocarcinoma (cT1cN3M1c Stage IVB) with choroid metastases. The tumour proportion score of programmed death ligand 1 (PD-L1) was 1% and EGFR exon 20 insertion mutations were also detected. The patient was administered combination chemotherapy with nivolumab and ipilimumab. Primary lung and metastatic tumours, including the choroid, were reduced, and visual disturbances improved completely. Herein, we describe a rare case in which a combination of chemotherapy with nivolumab and ipilimumab significantly reduced vision loss due to choroidal metastasis.

    DOI： 10.1002/rcr2.1262

    Scopus

    PubMed

  • Matsuyama T., Kubota K., Tsuruzono K., Uchida H., Hamasaki T., Mizuno K., Inoue H. .  Primary mediastinal choriocarcinoma requiring differentiation from non-small cell lung cancer: An autopsy case report .  Respiratory Medicine Case Reports50   102037   2024.1Reviewed International journal

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)   Publisher：Respiratory Medicine Case Reports  

    A 65-year-old man with dyspnea and hemoptysis presented with a right upper lobe mass associated with enlarged mediastinal lymph nodes and bilateral pulmonary nodules on chest computed tomography (CT), suspected lung cancer. Bronchial and CT-guided biopsies revealed poorly differentiated carcinoma. His condition deteriorated rapidly before a definitive diagnosis could be made. Autopsy revealed primary mediastinal choriocarcinoma. Primary mediastinal choriocarcinomas are rare, difficult to diagnose early and have a poor prognosis. In patients with a tumor expanding across the lung and mediastinum and exhibiting pathologic findings of a pooly differentiated carcinoma, we should consider choriocarcinoma, evaluating the serum β-human chorionic gonadotropin levels.

    DOI： 10.1016/j.rmcr.2024.102037

    Scopus

    PubMed

  • 窪田 幸司, 水野 圭子, 安田 俊介, 松山 崇弘, 濱崎 哲郎, 井上 博雅 .  アテゾリズマブ投与後に抗リカバリン抗体陽性の網膜症を発症した小細胞肺癌の1例 .  日本呼吸器学会誌11 ( 6 ) 345 - 349   2022.11Reviewed

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)   Publisher：(一社)日本呼吸器学会  

    症例は86歳,男性.進展型小細胞肺癌と診断し,カルボプラチン(carboplatin)+エトポシド(etoposide)+アテゾリズマブ(atezolizumab)による1次治療を開始した.4コースの化学療法終了後,両眼の急速な視力低下が出現した.精査の結果,抗リカバリン抗体陽性の網膜症と診断した.アテゾリズマブの中止とステロイド治療により,視力障害は軽快した.肺癌の治療開始後に自己免疫機序の網膜症が発症することは稀であり,免疫チェックポイント阻害剤が関連している可能性が考えられた.(著者抄録)

  • 里村 緑, 美園 俊祐, 米 未紀子, 冨岡 勇也, 大脇 一人, 松山 崇弘, 高木 弘一, 三山 英夫, 末次 隆行, 井上 博雅 .  若年女性に発症した結核性ぶどう膜炎の1例 .  結核97 ( 5 ) 273 - 277   2022.7Reviewed

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)   Publisher：(一社)日本結核・非結核性抗酸菌症学会  

    症例は25歳女性。右眼の見えにくさを主訴に当院眼科を受診し,蛍光眼底検査で結核性ぶどう膜炎を疑われた。インターフェロンガンマ遊離試験(Interferon-gamma release assay:IGRA)が陽性であり,胸部単純X線検査で右上肺野に粒状影を認め,体幹部CTで右肺上葉S2に小葉中心性の粒状影と浸潤影を,左肺上葉にもわずかに粒状影を認めた。喀痰抗酸菌検査は陰性であり,経気管支生検でラングハンス型多核巨細胞を伴う壊死性肉芽腫を認めた。画像所見,IGRA陽性およびその他の検査結果とあわせて,肺結核および結核性ぶどう膜炎と診断した。抗結核薬の標準治療(イソニアジド,リファンピシン,エタンブトール,ピラジナミド)を開始し,治療2ヵ月後のCTで両側肺野の粒状影,浸潤影は消退傾向であった。右眼の症状については,経過中に硝子体出血を合併したため,硝子体手術を施行し,症状は回復した。結核性ぶどう膜炎は診断の遅れが失明につながる可能性がある。そのため,眼科と密な連携をとり,早期診断,早期治療介入を行う必要がある。(著者抄録)

  • Seiya Takada, Harutoshi Sakakima, Takahiro Matsuyama, Shotaro Otsuka, Kazuki Nakanishi, Kosuke Norimatsu, Yuki Itashiki, Akira Tani, Kiyoshi Kikuchi .  Disruption of Midkine gene reduces traumatic brain injury through the modulation of neuroinflammation .  Journal of Neuroinflammation17   40   2020.1Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1186/s12974-020-1709-8

  • Koichi Takagi, Munekazu Yamakuchi, Takahiro Matsuyama, Kiyotaka Kondo, Akifumi Uchida, Shunsuke Misono, Teruto Hashiguchi, Hiromasa Inoue .  IL-13 enhances mesenchymal transition of pulmonary artery endothelial cells via down-regulation of miR-424/503 in vitro .  Cell Signaling42   270 - 280   2018.1Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Bilateral Diffuse Uveal Melanocytic Proliferation(BDUMP)による視覚障害が発見動機となった肺扁平上皮癌の1例 新村 昌弘, 濱崎 大智, 松山 崇弘, 高木 弘一, 貞村 ゆかり, 籾 博晃, 東元 一晃, 井上 博雅 .  Bilateral Diffuse Uveal Melanocytic Proliferation(BDUMP)による視覚障害が発見動機となった肺扁平上皮癌の1例 .  日本呼吸器学会雑誌49 ( 3 ) 187 - 191   2011.3Reviewed

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • 松山 崇弘, 是枝 快房, 中塩屋 二郎, 濱田 美奈子, 富山 由美子, 川畑 政治 .  壊死性肉芽腫を伴いサルコイドーシスとの鑑別に苦慮した肺結核症の1例 .  日本呼吸器学会雑誌49 ( 10 ) 775 - 779   2011.1Reviewed

    　More details

    Authorship：Lead author   Language：Japanese   Publishing type：Research paper (scientific journal)  

  • 松山 崇弘, 貞村 ゆかり, 川端 隆史, 籾 博晃, 東元 一晃 .  粟粒結核治療中に出現した結核性外側広筋膿瘍の1例 .  日本呼吸器学会雑誌48 ( 9 ) 702 - 705   2010.9Reviewed

    　More details

    Authorship：Lead author   Language：Japanese   Publishing type：Research paper (scientific journal)  

▼display all

MISC

  • 特集 気管支喘息　古くて新しい疾患 ICS/ホルモテロール頓用治療の功罪

    松山 崇弘, 井上 博雅

    Medical Practice   41 ( 1 )   96 - 99   2024.1

    　More details

    Authorship：Lead author   Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)   Publisher：(株)文光堂  

    DOI： 10.50936/j01778.2024121814

    CiNii Research

  • 【気管支喘息　古くて新しい疾患】ICS/ホルモテロール頓用治療の功罪

    松山 崇弘, 井上 博雅

    Medical Practice   41 ( 1 )   96 - 99   2024.1

    　More details

    Authorship：Lead author   Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)   Publisher：(株)文光堂  

  • 治療法の再整理とアップデートのために　専門家による私の治療　喘息とCOPDのオーバーラップ(ACO)

    松山 崇弘, 高木 弘一, 井上 博雅

    日本医事新報   ( 5148 )   40 - 41   2022.12

    　More details

    Authorship：Lead author   Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)   Publisher：(株)日本医事新報社  

  • 【免疫・アレルギー炎症細胞の新知見】ILC2を介する好酸球性気道炎症における長時間作用性ムスカリン受容体拮抗薬の抑制効果

    松山 崇弘

    臨床免疫・アレルギー科   77 ( 3 )   325 - 333   2022.3

    　More details

    Authorship：Lead author   Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)   Publisher：(有)科学評論社  

  • 【COPDと喘息-診療の最前線】COPDと喘息の病態生理

    松山 崇弘, 高木 弘一, 井上 博雅

    臨牀と研究   98 ( 9 )   1019 - 1025   2021.9

    　More details

    Authorship：Lead author   Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)   Publisher：大道学館出版部  

  • 【花粉症と周辺疾患】気管支喘息への影響と対策

    松山 崇弘, 高木 弘一, 町田 健太朗, 井上 博雅

    アレルギーの臨床   40 ( 2 )   95 - 98   2020.2

    　More details

    Authorship：Lead author   Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)  

  • 【診断と治療のABC[135]喘息】(第2章)病理・病態生理　病態生理

    松山 崇弘, 町田 健太朗, 井上 博雅

    最新医学   56 - 63   2018.6

    　More details

    Authorship：Lead author   Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)  

  • 【アレルギー疾患の新しい治療】気管支喘息の分子標的薬療法

    松山 崇弘, 東元 一晃, 井上 博雅

    アレルギーの臨床   36 ( 11 )   1031 - 1034   2016.10

    　More details

    Authorship：Lead author   Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)  

  • アレルギー疾患　治療の最新トピックス　内科　喘息における生物学的製剤の現況と今後の展望

    松山 崇弘, 高木 弘一, 井上 博雅

    日本医師会雑誌   145   S326 - S327   2016.6

    　More details

    Authorship：Lead author   Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)  

▼display all

Presentations

  • 8. 黒岩大俊, 松山崇弘, 亀之原佑介, 坂上公太, 新村昌弘, 高木弘一, 三山英夫, 籾博晃, 町田健太朗, 井上博雅   当院におけるCOPDおよびACO患者の臨床的特徴に関する検討  

    第60回日本呼吸器学会学術講演会  2020.9 

    　More details

    Language：Japanese   Presentation type：Poster presentation  

    Venue：神戸   Country：Japan  

  • Y.Dotake, T.Matsuyama, K.Takagi, H.Matsuyama, K.Machida, H.Inoue   A cation-selective transmembrane protein has an important role in cold-induced airway eosinophilic inflammation  

    2024.4 

    　More details

    Language：English   Presentation type：Oral presentation (general)  

    Country：Japan  

  • Effects of instructional materials on inhaler technique   International conference

    The 27th Congress of Interasma Japan / North Asia  2017.10 

    　More details

    Language：English   Presentation type：Poster presentation  

    Venue：Kumamoto   Country：Japan  

  • 2. T.Matsuyama, K.Machida, K.Sakaue, A.Tanoue, K.Takagi, I.Higashimoto, H.Inoue   Tiotropium Bromide Suppresses Airway Inflammation in Mouse Model of Asthma   International conference

    ATS 2019 conference  2019.5 

    　More details

    Language：English   Presentation type：Poster presentation  

    Venue：Dallas   Country：United States  

  • T.Matsuyama, K.Machida, K.Sakaue, A. K.Takagi, H.Inoue   TRPA1-deficient mice were suppressed airway inflammation in a papain induced model   International conference

    ATS 2019 conference  2019.5 

    　More details

    Language：English   Presentation type：Poster presentation  

    Venue：Dallas   Country：United States  

  • T.Matsuyama, K.Machida, Y.Doutake, K.Takagi, H.Inoue   TRPA1 channel mediates cold air-induced aggravation of airway inflammation   International conference

    JSA/WAO Joint Congress  2020.9 

    　More details

    Language：English   Presentation type：Poster presentation  

    Venue：Kyoto   Country：Japan  

  • T.Matsuyama, K.Machida, H.Matsuyama, Y.Dotake, K.Takagi, H.Inoue   Long-acting Muscarinic Antagonist Attenuated Human Basophil-Derived IL-4 Production   International conference

    ATS 2022 conference  2022.5 

    　More details

    Language：English   Presentation type：Poster presentation  

    Venue：San Francisco   Country：United States  

  • T.Matsuyama, K.Machida, H.Matsuyama, Y.Dotake, K.Takagi, H.Inoue   The Effect of Long-acting Muscarinic Antagonist on Airway Inflammation through Leukotrienes  

    ATS2023 conference  2023.5 

    　More details

    Language：English   Presentation type：Poster presentation  

    Venue：Washington DC   Country：United States  

  • T. Matsuyama, Y. Tokunaga, X. Ju, N. Fard, N. Diab, D. Brister, W. Hassan, M. Wahab, E. Kum, J. Wattie, K. Howie, K. Killian, J. Smith, G. Gauvreau, P. O’Byrne, I. Satia, R. Sehmi   Immunomodulatory effects of Mepolizumab on group 2 innate lymphoid cells in patients with refractory chronic cough and eosinophilic airways disease (MUCOSA)   International coauthorship International conference

    ERS2025 Conference  2025.9 

    　More details

    Language：English   Presentation type：Poster presentation  

    Venue：Amsterdam   Country：Netherlands  

  • T.Matsuyama, Y.Tokunaga, X.Ju, N.Diab, D.Brister, M.Wahab, E.Kum, J.Wattie, K.Howie, K.Killian, J.Smith, G.M. Gauvreau, P.M. O’Byrne, I.Satia, R.Sehmi   A comparative analyses of group 2 innate lymphoid cells in sputum from patients with non-asthmatic eosinophilic bronchitis and allergic asthma   International coauthorship International conference

    ERS2024 Conference  2024.9 

    　More details

    Language：English   Presentation type：Oral presentation (general)  

    Venue：Vienna   Country：Austria  

  • 松山崇弘   好酸球性喘息の治療標的としての2型自然リンパ球の意義  

    第64回日本呼吸器学会学術講演会  2024.4 

    　More details

    Language：Japanese   Presentation type：Symposium, workshop panel (nominated)  

    Venue：横浜   Country：Japan  

  • 松山崇弘，高木弘一，井上博雅   気管支喘息の治療における吸入手技と服薬アドヒアランスの重要性  

    第91回日本呼吸器学会・日本結核 非結核性抗酸菌症学会・日本サルコイドーシス／肉芽腫性疾患学会九州支部秋季学術講演会  2022.10 

    　More details

    Language：Japanese   Presentation type：Symposium, workshop panel (nominated)  

    Venue：宮崎   Country：Japan  

  • 松山崇弘   気管支喘息における 2 型自然リンパ球の役割と治療標的としての可能性  

    第89回日本呼吸器学会・日本結核 非結核性抗酸菌症学会・日本サルコイドーシス／肉芽腫性疾患学会九州支部秋季学術講演会  2021.10 

    　More details

    Language：Japanese   Presentation type：Symposium, workshop panel (nominated)  

    Venue：熊本  

  • Takahiro Matsuyama   ILC2 and basophils in asthma   International conference

    The 25th Congress of the Asian Pacific Society of Respirology  2021.11 

    　More details

    Language：English   Presentation type：Symposium, workshop panel (nominated)  

    Venue：Kyoto   Country：Japan  

  • 井上 博雅, 松山 洋美, 町田 健太朗, 高木 弘一, 堂嶽 洋一, 柳原 豊史, 松山 崇弘   難治性喘息におけるステロイド抵抗性の病態解析  

    第64回日本呼吸器学会学術講演会  2024.4  (一社)日本呼吸器学会

    　More details

    Language：Japanese   Presentation type：Symposium, workshop panel (nominated)  

  • 松山 洋美, 堂嶽 洋一, 松山 崇弘, 高木 弘一, 町田 健太朗, 井上 博雅   合併症を有する気管支喘息に対する長時間作用性抗コリン薬追加投与の効果の検討  

    第72回日本アレルギー学会学術大会  2023.10  (一社)日本アレルギー学会

    　More details

    Language：Japanese   Presentation type：Oral presentation (general)  

    Venue：東京   Country：Japan  

  • 松山 洋美, 高木 弘一, 堂嶽 洋一, 松山 崇弘, 三山 英夫, 町田 健太朗, 井上 博雅   当院における重症喘息に対するTezepelumabの臨床的有用性の検討  

    第73回日本アレルギー学会学術大会  2024.10  (一社)日本アレルギー学会

    　More details

    Language：Japanese   Presentation type：Poster presentation  

    Venue：京都   Country：Japan  

  • 松山 崇弘, 松山 洋美, 堂嶽 洋一, 高木 弘一, 町田 健太朗, 井上 博雅   当院における好酸球性肉芽腫性多発血管炎(EGPA)の臨床的検討  

    第70回日本アレルギー学会学術大会  2021.10  (一社)日本アレルギー学会

    　More details

    Language：Japanese   Presentation type：Oral presentation (general)  

    Venue：横浜   Country：Japan  

  • 大庭 優士, 松山 崇弘, 松山 洋美, 堂嶽 洋一, 高木 弘一, 三山 英夫, 久保田 真吾, 末次 隆行, 町田 健太朗, 井上 博雅   当院における好酸球性多発血管炎性肉芽腫症(EGPA)に対する生物学的製剤投与例の臨床的検討  

    第62回日本呼吸器学会学術講演会  2022.4  (一社)日本呼吸器学会

    　More details

    Language：Japanese   Presentation type：Poster presentation  

    Venue：京都   Country：Japan  

  • 松山 崇弘, 堂嶽 洋一, 近藤 清貴, 高木 弘一, 町田 健太朗, 井上 博雅   好酸球性気道炎症に対するチオトロピウムの効果  

    第61回日本呼吸器学会学術講演会  2021.4  (一社)日本呼吸器学会

    　More details

    Language：Japanese   Presentation type：Oral presentation (general)  

    Venue：東京   Country：Japan  

  • 高木 弘一, 松山 崇弘, 堂嶽 洋一, 松山 洋美, 三山 英夫, 町田 健太朗, 井上 博雅   好酸球性多発血管炎性肉芽腫症(EGPA)に対するMepolizumabの有用性の検討  

    第73回日本アレルギー学会学術大会  2024.10  (一社)日本アレルギー学会

    　More details

    Language：Japanese   Presentation type：Oral presentation (general)  

    Venue：京都   Country：Japan  

  • 松山崇弘, 東元一晃, 田上あさ子, 井上博雅   吸入デバイス説明媒体は手技習得にどれくらい有用か  

    第66回日本アレルギー学会学術大会  2017.10 

    　More details

    Language：Japanese   Presentation type：Oral presentation (general)  

  • 松山 洋美, 町田 健太朗, 堂嶽 洋一, 松山 崇弘, 高木 弘一, 田中 謙太郎, 井上 博雅   TL1A/DR3(Death receptor3)シグナルを介したILC2のアポトーシス抑制  

    第65回日本呼吸器学会学術講演会  2025.4  (一社)日本呼吸器学会

    　More details

    Language：Japanese   Presentation type：Oral presentation (general)  

    Venue：東京   Country：Japan  

  • 堂嶽 洋一, 松山 崇弘, 高木 弘一, 松山 洋美, 町田 健太朗, 田中 謙太郎, 井上 博雅   寒冷刺激に伴う好酸球性気道炎症に対するTRPA1チャネルの役割  

    第65回日本呼吸器学会学術講演会  2025.3  (一社)日本呼吸器学会

    　More details

    Language：Japanese   Presentation type：Oral presentation (general)  

    Venue：東京   Country：Japan  

  • Dotake Yoichi, Matsuyama Takahiro, Matsuyama Hiromi, Takagi Koichi, Machida Kentaro, Inoue Hiromasa   TRPA1チャネルは冷風による気道炎症の悪化を媒介する(Molecular and cellular diversity of allergic diseases(II)　TRPA1 channel mediates cold air-induced aggravation of airway inflammation)  

    第51回日本免疫学会学術集会  2022.12  (NPO)日本免疫学会

    　More details

    Language：English   Presentation type：Poster presentation  

    Venue：熊本   Country：Japan  

  • 松山 崇弘   好酸球性喘息の治療標的としての2型自然リンパ球の意義  

    第64回日本呼吸器学会学術講演会  2024.4  (一社)日本呼吸器学会

    　More details

    Language：Japanese   Presentation type：Symposium, workshop panel (nominated)  

  • H.Matsuyama, K.Machida, Y.Dotake, T.Matsuyama, K.Takagi, K.Tanaka, H.Inoue   TL1A/DR3 signaling mediates corticosteroid insensitivity in ILC2s  

    第53回日本免疫学会学術集会  2024.12  (NPO)日本免疫学会

    　More details

    Language：English   Presentation type：Poster presentation  

    Venue：長崎   Country：Japan  

  • 内村 慶, 高木 弘一, 畑中 将志, 山口 晃弘, 松山 洋美, 堂嶽 洋一, 松山 崇弘, 町田 健太朗, 田中 謙太郎, 井上 博雅   2型炎症を有する軽症から中等症のCOPDに対するtriple製剤の有用性  

    第65回日本呼吸器学会学術講演会  2025.4  (一社)日本呼吸器学会

    　More details

    Language：Japanese   Presentation type：Poster presentation  

    Venue：東京   Country：Japan  

  • 5. 東元一晃, 町田健太朗, 金澤裕信, 岩川純, 濱崎哲郎, 末次隆行, 是枝快泉, 窪田幸司, 佃屋剛, 松山崇弘, 田上あさ子, 井上博雅   鹿児島県内の呼吸器学会認定 / 関連施設における重症喘息の実態  

    第58回日本呼吸器学会学術講演会  2018.4 

    　More details

    Language：Japanese   Presentation type：Poster presentation  

    Venue：大阪   Country：Japan  

  • 6. 田村浩子, 松山崇弘, 坂上公太, 高木弘一, 籾博晃, 町田健太朗, 井上博雅   当院のサルコイドーシス長期経過観察による増悪因子の検討  

    第59回日本呼吸器学会学術講演会  2019.4 

    　More details

    Venue：東京   Country：Japan  

  • 7. 高木弘一, 町田健太朗, 松山崇弘, 坂上公太, 福田宏正, 窪田幸司, 岩川純, 井上博雅   鹿児島大学病院における難治性喘息の実態  

    第59回日本呼吸器学会学術講演会  2019.4 

    　More details

    Language：Japanese   Presentation type：Poster presentation  

  • 高木弘一、畑中将志、山口晃弘、松山洋美、堂嶽洋一、松山崇弘、町田健太朗、田中謙太郎、井上博雅   慢性過敏性肺炎における予後因子の検討  

    第65回日本呼吸器学会学術講演会  2025.4 

    　More details

    Language：Japanese   Presentation type：Poster presentation  

  • 松山 洋美, 松山 崇弘, 安田 俊介, 冨岡 勇也, 大脇 一人, 美園 俊祐, 近藤 清貴, 三山 英夫, 末次 隆行, 水野 圭子, 井上 博雅   経気管支肺生検で診断し得た軟骨肉腫肺転移の一例  

    第45回日本呼吸器内視鏡学会学術集会  2022.6  (一社)日本呼吸器内視鏡学会

    　More details

    Language：Japanese   Presentation type：Poster presentation  

    Venue：岐阜   Country：Japan  

  • 高木 弘一, 山口 晃弘, 畑中 将志, 松山 洋美, 堂嶽 洋一, 松山 崇弘, 町田 健太朗, 田中 謙太郎, 井上 博雅   慢性過敏性肺炎における予後因子の検討  

    第65回日本呼吸器学会学術講演会  2025.4  (一社)日本呼吸器学会

    　More details

    Language：Japanese   Presentation type：Poster presentation  

  • 冨岡 勇也, 松山 崇弘, 安田 俊介, 大脇 一人, 美園 俊祐, 三山 英夫, 末次 隆行, 水野 圭子, 井上 博雅   妊娠中に気管内に静脈瘤が観察されたKlippel-Trenaunay-Weber症候群の1例  

    第45回日本呼吸器内視鏡学会学術集会  2022.6  (一社)日本呼吸器内視鏡学会

    　More details

    Language：Japanese   Presentation type：Poster presentation  

    Venue：岐阜   Country：Japan  

  • 東元一晃, 田上あさ子, 松山崇弘, 井上博雅   喘息吸入指導教育 (ロールプレイを含む) がもたらす薬剤師自己評価への効果と相互評価の検討  

    第66回日本アレルギー学会学術大会  2017.10 

    　More details

    Language：Japanese   Presentation type：Poster presentation  

    Venue：東京   Country：Japan  

  • 田上あさ子, 武富芳隆, 町田健太朗, 松山崇弘, 村上誠, 井上博雅   III型分泌性ホスホリパーゼA2は気管支喘息を抑制する  

    第57回日本呼吸器学会学術講演会  2017.4 

    　More details

    Language：Japanese   Presentation type：Poster presentation  

    Venue：東京  

  • 松山崇弘, 久保田真吾, 山元滋樹, 内田章文, 岩川純, 金澤裕信, 水野圭子, 寒川卓哉, 東元一晃, 井上博雅,   縦隔気腫を合併した間質性肺炎の臨床的検討  

    第55回日本呼吸器学会学術講演会  2015.4 

    　More details

    Language：Japanese   Presentation type：Poster presentation  

    Venue：東京   Country：Japan  

  • 大庭 優士, 安田 俊介, 鶴薗 健太郎, 冨岡 勇也, 松山 崇弘, 三山 英夫, 末次 隆行, 水野 圭子, 井上 博雅, 田畑 和宏, 谷本 昭英   イピリムマブ+ニボルマブ+カルボプラチン+ペメトレキセド併用療法で視力の改善が得られた脈絡膜転移を有する肺腺癌の1例  

    第62回日本肺癌学会九州支部学術集会・第45回日本呼吸器内視鏡学会九州支部総会  2022.2 

    　More details

    Language：Japanese   Presentation type：Oral presentation (general)  

    Venue：久留米   Country：Japan  

  • 高木 弘一, 畑中 将志, 山口 晃弘, 松山 洋美, 堂嶽 洋一, 松山 崇弘, 町田 健太朗, 田中 謙太郎, 井上 博雅   COPDに対するLAMA/LABA治療効果における2型炎症の影響  

    第65回日本呼吸器学会学術講演会  2025.4  (一社)日本呼吸器学会

    　More details

    Language：Japanese   Presentation type：Poster presentation  

▼display all